Oncology

Overtreatment of prostate cancer persists among men with limited life expectancy within the Veterans Affairs (VA) health system.

A genetic variant, the BIM deletion polymorphism (BDP), has been identified by researchers to significantly enhance leukemia stem and progenitor cells’ survival, making them resistant to common targeted therapies.

A powerful link between health insurance status and racial and ethnic disparities in advanced cancer diagnoses has been identified in a recently published study.

Prognostic value of specific visceral protein ratios in patients with colon cancer can offer healthcare professionals a novel approach to estimating progression-free survival (PFS) and overall survival (OS) in affected patients.

A recent study sheds light on how estrogen signaling affects immune response in breast cancer, potentially opening pathways for combined anti-estrogen and immunotherapy approaches.

Nearly half of patients with metastatic melanoma treated with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab have survived cancer-free, underscoring the impact of immunotherapy in advanced melanoma.

Duloxetine, a widely used and popular antidepressant, has been recalled by U.S. Food and Drug Administration (FDA) due to the detection of N-nitroso-duloxetine, a chemical suspected of being carcinogenic.

Diet quality could play a role in the progression of prostate cancer for men undergoing active surveillance.